Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

FLUOX-PMS Study Grp, Melissa Cambron, Jop Mostert, Marie D'Hooghe, Guy Nagels, Barbara Willkens, Jan Debruyne, Luc Algoed, Winn Verhagen, Raymond Hupperts, Dorothea Heersema, Jacques De Keyser*

*Bijbehorende auteur voor dit werk

    Onderzoeksoutput: ArticleAcademicpeer review

    12 Citaten (Scopus)


    Background: Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS). Objective: To determine whether fluoxetine slows accumulation of disability in progressive MS. Methods: In a double-blind multicenter phase 2 trial, patients with primary or secondary progressive MS were randomized to fluoxetine 40 mg/day or placebo for a period of 108 weeks. Clinical assessments were performed every 12 weeks by trained study nurses who visited the patients at their home. The primary outcome was the time to a 12-week confirmed 20% increase in the Timed 25 Foot Walk or 9-Hole Peg test. Secondary outcomes included the Hauser ambulation index, cognitive tests, fatigue, and brain magnetic resonance imaging (MRI). Results: In the efficacy analysis, 69 patients received fluoxetine and 68 patients received placebo. Using the log-rank test (p = 0.258) and Cox regression analysis (p = 0.253), we found no significant difference in the primary outcome between the two groups. Due to an unexpected slow rate of progression in the placebo group, there was insufficient statistical power to detect a potential benefit of fluoxetine. We found no differences between the two groups for secondary outcomes. Conclusion: The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS.

    Originele taal-2English
    Pagina's (van-tot)1728-1735
    Aantal pagina's8
    TijdschriftMultiple sclerosis journal
    Nummer van het tijdschrift13
    StatusPublished - nov-2019

    Citeer dit